Asthma

Scene Health and CareFirst Expand Partnership for Medicaid Members

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Professional Services, Managed Care, Other Health, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Insurance, Clinical Trials, Culture, Johns Hopkins, Entrepreneurship, Partnership, CareFirst BlueCross BlueShield, Patient, Prescription, Asthma, Quality, Medicaid, Multimedia, Medicine, Hypertension, Pharmaceutical industry

Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.

Key Points: 
  • Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.
  • “Our partnership with Scene has helped deepen our understanding of the real-life experiences and challenges members were facing,” said Mike Rapach, President and CEO of CareFirst Community Health Plan Maryland (CHPMD).
  • “We are grateful for five years of outstanding partnership with CareFirst BlueCross BlueShield of Maryland’s Medicaid team.
  • “Innovations such as Scene Health's services seamlessly coordinated with other CareFirst health services, benefits, and rich network coverage are critical for us to improve the overall health and quality of care for our members."

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Retrieved on: 
Monday, March 18, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Disease, Patient, LTP, Hereditary angioedema, HAE, Quality of life, Anxiety, University, KALV, Return, Treatment, Quality, Asthma, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
  • “These data show once again that people living with HAE still face challenges in following established guidelines for treating their attacks,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • “Even short treatment delays can lead to worse clinical outcomes, and despite efficacious on-demand treatments, the fact that they need to be injected results in barriers which lead to significant underuse and resultant overuse of long-term prophylaxis.
  • (Poster Presentation)
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Managed Care, General Health, Oncology, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Surgery, Biotechnology, Nursing, Medical Supplies, Practice Management, Health, Growth, Prevalence, Application, Molecular Modeling Database, Incidence, Patient, Ventilation, Hospital, Acute respiratory distress syndrome, GE HealthCare, Asthma, Medtronic, COPD, Nursing care plan, ICU, USD, Ageing, Medical device

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.

ChestPal™ Pro, a Bluetooth-Connected, Portable, Crackle and Wheeze Detection Innovation, Launches in the U.S. as Early Asthma and Allergy Season Looms

Retrieved on: 
Tuesday, March 12, 2024
Hardware, Health Technology, Health Insurance, Data Management, Other Health, Technology, Oncology, General Health, Biometrics, Medical Devices, Hospitals, Biotechnology, Software, Health, Medical Supplies, Mobile, Wireless, Diagnosis, MD, Wheeze, COPD, Patient, Lung, Multimedia, Asthma, Steroid, Classification, Pneumonia, Glimpse, Internal medicine, Entrepreneurship

ChestPal™ Pro, the only commercially available digital stethoscope in the U.S. that’s clinically backed to detect, classify, record, and share crackles and wheezes, launches to healthcare practitioners today.

Key Points: 
  • ChestPal™ Pro, the only commercially available digital stethoscope in the U.S. that’s clinically backed to detect, classify, record, and share crackles and wheezes, launches to healthcare practitioners today.
  • This press release features multimedia.
  • ​​For clinicians who need to accurately detect, record, and share classified lung sounds.
  • “ChestPal™ Pro helps pick up lung sounds that are too subtle to hear when using a stethoscope alone,” said Dr. Emily Tuchman, MD, General Internal Medicine.

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Mutation, Disease, RNA, Doctor of Philosophy, IND, Life expectancy, Asthma, IPF, Idiopathic pulmonary fibrosis, Investigational New Drug, Bronchiectasis, CFTR, COPD, FDA, Cystic fibrosis, Food, Pharmaceutical industry

JERUSALEM, April 3, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma, non-CF bronchiectasis (NCFB) and idiopathic pulmonary fibrosis (IPF), today announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 study for SPL84 in CF. SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key Points: 
  • SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • The Company has also announced today that it has secured funding from the CF Foundation and other existing investors to support the SPL84 Phase 2 study and additional pulmonary programs.
  • "We are excited to initiate the Phase 2 study for SPL84 in CF with the support of the CF Foundation and other existing investors," said Gili Hart, PhD, Chief Executive Officer of SpliSense. "
  • Our lead product, SPL84, has been shown to fully restore CFTR activity in the CF gold standard pharmacological model.

Lindus Health Unveils Versatile "All-in-One Respiratory CRO" Offering Tailored to Respiratory Clinical Trials

Retrieved on: 
Tuesday, April 2, 2024
Sleep apnea, Pneumonia, MIT, Electronic data capture, Patient, Chronic obstructive pulmonary disease, Research, Pi, Health information management, EDC, Electronic health record, MD, Respiratory disease, Asthma, CTMS, Housing, Clinical trial management system, COPD, Data management, AptarGroup, Clinical data management, Fine chemical

Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.

Key Points: 
  • Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.
  • "We're thrilled to be launching a bespoke CRO offering to respiratory disease sponsors to mitigate the challenges faced in bringing essential respiratory therapies to market."
  • Deep regulatory and therapeutic area-specific expertise: Bringing together various research backgrounds, the Lindus Health team resumes exceptional expertise within respiratory clinical trials and the ever-changing regulatory landscapes of the US, UK, and EU.
  • Lindus Health is committed to leading successful respiratory research, providing a robust and efficient framework for clinical trials from inception to completion, and enhancing the experience for both sponsors and participants.

Open waste burning linked to air pollution in Northwestern Greenland

Retrieved on: 
Tuesday, April 2, 2024
Death, Health, Bronchitis, SDG, Associate, Environmental science, Public, Sustainable Development Goals, Research, University, Smoke, NOAA, Hokkaido University, HYSPLIT, Nagoya University, Particulates, Asthma, Dust, NASA, Atmospheric Science Letters, Air pollution, Coal

SAPPORO, Japan, April 2, 2024 /PRNewswire/ -- To better understand the air quality risks faced by remote Arctic communities, an international team monitored aerial pollutants at a community in Northwestern Greenland. Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.

Key Points: 
  • A case study on the effects of open waste burning on air quality in Northwestern Greenland by Hokkaido University researchers calls attention to the importance of no-one-left-behind sustainable air quality monitoring in the Arctic region.
  • Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.
  • The study focused on Qaanaaq, a small village in Northwestern Greenland with a population of approximately 600.
  • We found out how much pollution increases with PM2.5 during local open waste burning," Yasunari said.

Open waste burning linked to air pollution in Northwestern Greenland

Retrieved on: 
Tuesday, April 2, 2024
Death, Health, Bronchitis, SDG, Associate, Environmental science, Public, Sustainable Development Goals, Research, University, Smoke, NOAA, Hokkaido University, HYSPLIT, Nagoya University, Particulates, Asthma, Dust, NASA, Atmospheric Science Letters, Air pollution, Coal

 SAPPORO, Japan, April 2, 2024 /PRNewswire/ -- To better understand the air quality risks faced by remote Arctic communities, an international team monitored aerial pollutants at a community in Northwestern Greenland. Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.

Key Points: 
  • A case study on the effects of open waste burning on air quality in Northwestern Greenland by Hokkaido University researchers calls attention to the importance of no-one-left-behind sustainable air quality monitoring in the Arctic region.
  • Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.
  • The study focused on Qaanaaq, a small village in Northwestern Greenland with a population of approximately 600.
  • We found out how much pollution increases with PM2.5 during local open waste burning," Yasunari said.